RXDX-105 (CEP-32496)

new

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:Agerafenib, also known as RXDX-105, CEP-32496 and AC013773, is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. CEP-32496 specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene.

Price and Availability

CEP-32496 (Agerafenib), purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 205903Name: RXDX-105 (CEP-32496)CAS#: 1188910-76-0 (free base)Chemical Formula:C24H22F3N5O5Exact Mass: 517.1573Molecular Weight: 517.47Elemental Analysis: C, 55.71; H, 4.29; F, 11.01; N, 13.53; O, 15.46

Synonym:RXDX-105; RXDX 105; RXDX105; CEP32496; CEP-32496; CEP 32496; AC013773; AC 013773; AC-013773. Agerafenib

IUPAC/Chemical Name:1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea

InChi Key:DKNUPRMJNUQNHR-UHFFFAOYSA-N

InChi Code:InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)

SMILES Code:O=C(NC1=NOC(C(C)(C)C(F)(F)F)=C1)NC2=CC=CC(OC3=C4C=C(OC)C(OC)=CC4=NC=N3)=C2

Technical Data

Additional Information

Related CAS#CAS#1188910-76-0 (free base)CAS#1227678-26-3 ( HCl salt).  

References

1: James J, Ruggeri B, Armstrong RC, Rowbottom MW,Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, CramerMD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE,Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, HolladayMW. CEP-32496: a novel orally active BRAF(V600E) inhibitor withselective cellular and in vivo antitumor activity. Mol Cancer Ther. 2012Apr;11(4):930-41. doi: 10.1158/1535-7163.MCT-11-0645. Epub 2012 Feb 7.PubMed PMID: 22319199.